Datla Human Immunome Lab - 51茶馆

51茶馆

Datla Human Immunome Lab

  • user
51茶馆

Other links:

Other links:

Banner
  • Home
  • Datla Human Immunome Lab

Datla Human Immunome Lab

Trivedi School of Bioscience, in 51茶馆, hosts the Datla Human Immunome Lab (DatlaHILab), a thematic research centre dedicated to research in human immunology, made possible by generous support from Dr. Vijay Kumar Datla Foundation, India.

The DatlaHILab is projected to address critical health challenges in South Asia and contribute to global scientific discourse with respect to both communicable and noncommunicable diseases. We envision this Lab not only as a centre for knowledge generation but as a catalyst for meaningful change in global health, through the lens of personalized medicine, public health intervention, and immunological innovation. By leveraging India’s distinct demographic and environmental factors, we aim to deepen our understanding of immune responses and their impact on human diseases such as infectious diseases, cancer, metabolic disorders, autoimmune diseases and aging. Another major focus of the DatlaHILab is projected to be on prospective cohort development for studies related to human immunology as well as for exploration of the human immune system within the 鈥極ne Health鈥� framework.

People听 Advisors听 51茶馆 and Outreach听 Facilities

Research

  • Exploring inflammatory disorders and inflammaging in Indian population: urban vs rural differences, lifestyle influences, impact of environment and ecological dynamics in the context of climate change and urbanization.
  • BCR and TCR diversity in urban and rural India, providing insight into infectious exposures, vaccine response heterogeneity 鈥� eventually contributing to capacity building for future pandemic preparedness.
  • Exploration of innate immune response in discrete clinical contexts in the Indian population. It is extremely likely that Indian data will add much new knowledge to current that is primarily from West, based on different degrees of pathogen exposure.
  • Mapping of cancer immunome for Breast Cancer, where we already have excellent sample access and networks. Initiation of work for other solid cancers, a number of them being very poorly studied in India so far. A major focus will also be on response heterogeneity to approved immune checkpoint blockade immunotherapies currently approved and administered in Indian clinics.
  • Multi-omics immunophenotyping in patient cohorts of autoimmune diseases and other autoreactive inflammatory diseases, to map heterogeneity of clinical presentations, disease progression and response to specific therapies.

Research

Sticky Button